Altesa Biosciences, co-led by former Assistant US Health Secretary Brett Giroir, has successfully raised $75 million in a Series B funding round aimed at advancing its anti-rhinoviral therapy for chronic obstructive pulmonary disease (COPD) into mid-stage clinical trials. This significant financial backing underscores the growing interest and investment in innovative treatments targeting respiratory diseases, particularly in the context of increasing prevalence and healthcare burdens associated with COPD.
The funding will facilitate the progression of Altesa’s lead candidate, Vapendavir, which has shown promise in preclinical studies for its ability to combat rhinovirus infections that exacerbate COPD symptoms. As regulatory scrutiny intensifies in the biopharmaceutical sector, this funding not only positions Altesa to enhance its research and development capabilities but also signals confidence from investors in the potential of targeted antiviral therapies. The implications of this funding extend beyond Altesa, highlighting a shift in the industry towards more specialized treatments that address unmet medical needs in chronic respiratory conditions.
Use the database as your supply chain compass →
